Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CARFILZOMIB vs CASIRIVIMAB\IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CARFILZOMIB vs CASIRIVIMAB\IMDEVIMAB: Safety Overview

Metric CARFILZOMIB CASIRIVIMAB\IMDEVIMAB
Total FAERS Reports 21,814 4,248
Deaths Reported 3,448 137
Death Rate 15.8% 3.2%
Hospitalizations 7,502 1,351
Average Patient Age 64.7 yrs 54.3 yrs
% Female Patients 42.6% 55.4%
FDA Approval Date Jul 20, 2012 N/A
Manufacturer Onyx Pharmaceuticals, Inc. N/A
Route INTRAVENOUS N/A
Marketing Status Prescription N/A